 Connection
Mark Lovell to Dementia
This is a "connection" page, showing publications Mark Lovell has written about Dementia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.583 |
|
|
|
-
Lovell MA, Abner E, Kryscio R, Xu L, Fister SX, Lynn BC. Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. Oxid Med Cell Longev. 2015; 2015:787805.
Score: 0.380
-
Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, Yee M, Crowley J, Schmitt FA. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). JAMA Neurol. 2017 05 01; 74(5):567-573.
Score: 0.108
-
Mehta SG, Watts GD, Adamson JL, Hutton M, Umberger G, Xiong S, Ramdeen S, Lovell MA, Kimonis VE, Smith CD. APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD). Genet Med. 2007 Jan; 9(1):9-13.
Score: 0.053
-
Lauterbach EC, Cummings JL, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans TA, Salloway SP. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 1998; 10(3):249-66.
Score: 0.028
-
Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, Xiong S, Gold BT. White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging. 2010 Jul; 31(7):1122-31.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|